melanoma prevalence increased by 225% between the lowest and the highest income group, but also that the prevalence of melanoma increased by 30% in rural as compared to urban areas. 15 The authors were not able to analyze patient outcomes related to stage at presentation, differential survival based on stage, or mortality in rural vs urban populations because of limitations of the database. Further, access to a dermatologist was not measured and could also have contributed to the observed relationship between prevalence and income status or rurality.
Therefore, this study was undertaken to investigate factors related to melanoma stage at presentation and prognosis in Ontario, Canada using a large, population-based cohort. The primary objective was to investigate whether rurality was associated with melanoma stage at presentation and with differential survival. Secondary objectives included investigating the association between other factors, including access to dermatologic care, stage at presentation, and patient survival. Finally, we explored whether rurality was confounded with access to a dermatologist, since it was hypothesized that the previous results showing an association between rurality and patient outcomes might be due to access to care issues.
Patients and Methods
This was a retrospective cohort study of patients diagnosed with melanoma cancer in Ontario, Canada between 2004 and 2012. All patients identified with melanoma using ICD-9 code 172.x in the Ontario Cancer Registry (OCR) were included. Nonresidents of Ontario and patients without pathologic confirmation of diagnosis were excluded. Additionally, since patients with prior cancers might have different disease trajectories, those patients with a previous cancer diagnosis within 5 years prior to diagnosis were also excluded.
We used multiple linked administrative databases to create our study cohort, which included the OCR for confirmed melanoma diagnosis, diagnosis date, and stage: Ontario Health Insurance Program (OHIP) for physician billings; Registered Persons Data Base (RPDB) for date of death and demographic information; and Canadian Institute for Health Information's Discharge Abstract Database (DAD) for hospital admissions. As a result of the universal health system in Canada, our analysis captures the vast majority of melanoma cases diagnosed during this time period. The study design was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre. All databases used for the study are housed at the Institute for Clinical Evaluative Sciences.
The outcomes of interest were stage at diagnosis and time to death. The distance to the nearest cancer center was measured from the center location of the individual's postal code region to the closest cancer center based on computerized driving distance. Second, the rural index of Ontario (RIO) score is a measurement of rurality with values ranging from 0 to 100. 16 A RIO score of 0 represents a large urban center with higher score indicating increasing rurality. The Ontario government defined a RIO (2008 version) score of 40 as the minimum RIO score for eligibility in the Rural Family Medicine Locum Program. 17 Hence, we used this cutoff based on RIO 2008 measurements. In addition, to provide greater information, additional cut-points were defined at 1 and 10 based on approximate tertiles. People were defined as being rural if they lived in a community with a population size of less than 10 000 people. Distance, RIO score, and rural community status were all used as different measures of individual patient rurality. Third, we measured the number of visits to a primary care physician or a dermatologist in the year prior to melanoma diagnosis. Physician specialization was identified by the specialty unique OHIP billing code used for an individual patient visit. Having seen a dermatologist and continued with the same general practitioner within the year prior to diagnosis was used as surrogates for access to care.
Descriptive statistics were used to summarize patient and disease characteristics, as well as outcomes. Cochran-Armitage test for trend and χ 2 tests were used to investigate whether distance, RIO score, or rurality were significant for stage at presentation. Logistic regression models were used to investigate if factors were prognostic for stage, with stage dichotomized into III and IV vs I and II for analytical purposes. Patients with unknown stage were excluded from this analysis.
For statistical normalization purposes, distance to cancer center and RIO score were transformed by adding 1 and then performing a logarithmic transformation. Categorization of factors were performed for statistical purposes. Wherever possible, categories were selected based on clinically important cut-points. For example, access to a dermatologist was defined as having any OHIP billing with a dermatologist specialist vs no such visit. A cut-point of 3 or more visits to the same general practitioner within 365 days was used to define having consistent access to family medical care. Information such as income and location (used to measure distance to the nearest cancer center, rural status, and RIO score) was calculated based on the geographic center of the patients' postal code. For privacy considerations, ages of individuals were categorized to be ≤24, by 5-year age groups to 84, or ≥85, and income status divided into quintiles. Information regarding Local Health Integration Networks (LHINs), which are 14 local regions within Ontario mandated to provide governance over regional care, remained blinded. The Charlson comorbidity index was dichotomized using 0 vs ≥1 for analysis.
Estimates of survival time were calculated using the Kaplan-Meier method. Cox proportional hazards regression was used to evaluate whether factors (age, gender, Charlson index, year of diagnosis, cancer >5 years prior to diagnosis, RIO score, distance from cancer center, rurality, LHIN, income quintile, family physician visits within 365 days prior to diagnosis, and visit to dermatologist within 365 days prior to diagnosis) were prognostic for survival. Multivariable models were constructed using forward stepwise selection with entry criteria of P-value <.05. All tests were 2-sided and statistical significance was defined as a P-value of .05 or less.
Results
Initially, 24 110 melanomas were diagnosed between 2004 and 2012 in Ontario, occurring in 20 388 individuals. Of the 20 388 individuals, 1612 (7.9%) were excluded due to having a previous or second cancer within 5 years, diagnosis being not pathologically confirmed, or the individual having no residential address, leaving 18 776 eligible patients (see Figure 1 ). Of these patients, 9591 (51.1%) had staging data available.
Patient and disease characteristics are summarized in Table 1 . Of patients with staging data available, the median age was approximately 60 years and 53% were male. Nearly 40% (7670) were diagnosed with stage I or II disease, 1921 (10%) were diagnosed with stage III or IV disease, and 49% were not staged. Most patients (62%) lived within 25 km of a cancer center, which corresponded to a RIO score ≤10 (62%). Over one-third (39%) of patients had been seen by a dermatologist within 365 days prior to melanoma diagnosis, while a small number (3.3%) had not been seen by a family physician in the preceding year. Notably, a statistically significant association was observed between RIO score, distance from a cancer center, and rurality (P < .001 for all) with having been seen by a dermatologist within 365 days prior to melanoma diagnosis (see Table 2 ).
Univariable and multivariable analyses evaluating factors associated with the presentation of an advanced stage are shown in Table 3 . In univariable analyses, males (odds ratio [OR] = 1.62, 95% confidence interval [CI] = 1.46-1.80) and patients having Charlson score ≥1 (OR = 1.34, 95% CI = 1.08-1.66) were at increased risk of higher stage disease at diagnosis, while those with a higher RIO score (OR = 0.97 per log-transformed unit, 95% CI = 0.93-1.00), who lived further from a cancer center (OR = 0.94 per log-transformed kilometer, 95% CI = 0.90-0.99), belonged in a higher income quintile (OR = 0.92 per quintile, 95% CI = 0.89-0.96), had seen a dermatologist (OR = 0.63, 95% CI = 0.57-0.71) or had 3 to 5 primary care physician visits (OR = 0.86, 95% CI = 0.76-0.97 vs those with ≤2 visits) were at decreased risk. Results were similar in multivariable analyses, with gender, prior dermatology visits, RIO score, LHIN, income quintile, year of diagnosis, distance from cancer center, and Charlson index entering the model. Note that the number of primary care physician visits did not enter the multivariable model (P-value = . 20) . No significant interaction between rurality (P = .19), RIO score (P = .73), and distance (P = .098) with family physician visits on stage at diagnosis was observed. Table 4 describes the factors associated with overall survival from the date of diagnosis. Patients who were older .12
Abbreviation: RIO, rural index of Ontario; KM, kilometers; RCC, regional cancer centre. days. No significant interaction between rurality (P = .068), RIO score (P = .18), and distance (P = .054) with family physician visits on survival outcomes was observed. The observed outcomes of patients by selected subgroups are presented in Table 5 to ease in interpretation. These results are unadjusted for other factors. As can be seen, even though distance from a cancer center and RIO score were significant prognostic factors of stage at diagnosis in the multivariable model, the absolute effect size was small. Of patients living >50 km from a cancer center, 18.6% were stage III or IV, compared with 21.5% of patients living <10 km away. Similarly, the rates of high stage cancer diagnosis were between 18.5% and 21.8% regardless of RIO category. Finally, a supportive analysis was performed by including those patients who had a previous cancer within 5 years prior to melanoma diagnosis, and the results were similar (data not shown). .003
Abbreviations: LHIN, Local Health Integration Networks; RIO, rural index of Ontario. Note: After adjusting for factors in the multivariable model, neither RIO score (categorical) nor distance (categorical) was statistically significant (P = .31 and .44, respectively). a As 14 regional LHIN categories remained blinded and reported only using dummy variables, they are not reported for simplicity. 
Discussion
Prior research showed an increase in melanoma prevalence for individuals in higher income groups as well as for individuals living in rural areas. 15 Having access to patient level data, this cohort study of all Ontario residents with pathologically confirmed melanoma diagnosed from 2004 to 2012 was conducted to explore whether income or residence location was associated with patient outcomes, including stage at diagnosis or overall survival following diagnosis. Rurality was defined in multiple ways, using the RIO score, distance to the nearest cancer center, and the patient's community size. It was hypothesized that access to care might be a confounding factor; thus, surrogate variables for access to care were defined using the frequency of visits to family physician and dermatology in the year preceding diagnosis. In this study, RIO score and distance from a cancer center were both statistically significant as prognostic for disease stage in both univariable and multivariable analyses, while rurality of residence was not significant. Although RIO score and distance were statistically significant prognostic factors of higher stage disease, the clinical importance of these results is unclear. The absolute proportion of stage III or IV diagnoses varied by <4% between the highest and lowest rates and is hindered by large numbers of patients with missing stage information. Further, no measure of residential location was statistically significant as a prognostic factor for survival once adjusted for other factors. The large sample sizes used for this study further implies that rurality likely has no clinically important impact on melanoma outcomes. There was a significant relationship between being seen by dermatology and melanoma outcomes. Patients seen by a dermatologist within 365 days prior to diagnosis were significantly less likely to present with stage III or IV disease (16% compared with 23%, OR = 0.58 in the multivariable model). Being seen by a dermatologist was also a prognostic factor for overall survival (HR = 0.73, 5-year OS of 63.6% vs 56.1%). This is in line with the previous findings from a Surveillance Epidemiology and End Results study which showed that patients who had seen both a primary care physician and a dermatologist in 2 years prior to diagnosis had thinner melanomas and decreased melanoma mortality. 18 Observational studies have also shown an earlier stage at diagnosis for dermatologist-diagnosed melanomas vs melanomas diagnosed by nondermatologists. 19 In addition, increasing dermatologist density has been associated with lower melanoma mortality. 13, 20 Although being seen by a dermatologist within 365 days prior to diagnosis is only a surrogate for access to care, these data strengthen the evidence supporting an association between dermatologist access and melanoma outcomes.
The fact that an increased number of primary care physician visits did not linearly correlate with decreased risk of detection of high stage disease may be due to the ability of family physicians to detect melanoma. A recent analysis correlating clinical and pathological melanoma in British Columbia, Canada found that dermatologists had diagnostic accuracy of 24.75% compared to only 3.52% by family physicians. 21 Patients who are seen by dermatologists may also have their melanomas detected at an earlier stage because of incidental detection during complete skin exams. A retrospective analysis of a single dermatology practice found that over 45% of melanomas were an incidental finding on full skin exam for an alternate complaint and that melanomas diagnosed in this way were on average thinner. 14 
Patients
with an established dermatologist are also more likely to self-diagnose earlier melanomas than those without a dermatologist. 22 Patients with 3 to 5 family physician visits had improved survival compared with those having 0 to 2 or 6+ visits. Patients with 0 to 2 visits may have limited comorbidities, limited access to family physicians, or may have chosen alternative practitioners for care (eg, dermatologists and naturopaths) prior to diagnosis. This highlights the limitations of this variable to be a true surrogate for access to family physician care.
This study is limited by the retrospective nature of the data. Despite accounting for known confounders, there may be variables which could not be captured in this analysis which could affect the results. For example, ethnic composition of patients and skin type, known prognostic factors for melanoma, 6 were unavailable in the current analysis. Another challenge with this dataset is the difficulty in defining access to primary care, with number of visits to a dermatologist or a general practitioner used in this analysis as potential surrogates. These factors may not entirely reflect access to care and are confounded by the severity of comorbidities prior to diagnosis. Additionally, to preserve patient anonymity, some data (ie, age, income, and LHIN) had to be categorized, losing some of its detail. Hence, certain patients likely have low income but live in a highincome postal code or vice versa, and the combining of data in this way may obscure some findings. Finally, this analysis is based on patients in Ontario, Canada, and it is possible that findings may not be generalizable to other regions which have different patterns of care or geographical variations.
A major strength of our data is the large number of patients included, with the database having access to all patients with a pathological diagnosis of melanoma in Ontario. Sampling such a broad spectrum of patients minimizes the biases seen in single practice and regional analyses and makes our results generalizable. Another strength is the ability to link individual patients' pathological stage and overall survival with prediagnosis physician visits. The previous studies have looked at average dermatologist numbers in geographic districts as a proxy for access to dermatological care while we were able to link this directly to patient level data.
In conclusion, this study demonstrates that rurality does not appear to be related to melanoma outcomes. The previous studies demonstrating such a link might be explained by the potential confounding of access to dermatology. In this study, rural patients were much less likely to have seen a dermatologist in the year prior to diagnosis than patients in more urban areas. Access to dermatology in Canada is a major public health issue and poor access to dermatology, particularly in areas further away from large cities, may lead to delayed melanoma diagnosis and worse patient outcomes. Public policy should focus on both increasing access to dermatologists in underserviced areas as well as identifying and providing targeted screening for high risk patients. Programs exist that aim to improve the dermatology and surgical skills of family physicians and these may allow for improved melanoma detection by the primary care physician.
